Eniluracil

Unknown / undisclosed

Also known as PCS6422

Ungradedevidence

Evidence outlook

Mid- and late-stage studies completed

This drug has completed mid- or late-stage studies. Where a sponsor has not posted registry results, topline data typically arrives via company announcements; see News.

Featured evidence outside this drug's tracked markets:NCT00003873 · Adenocarcinoma of the Colon · Phase 3 · completed · ungraded

Development in HR+/HER2- Metastatic Breast Cancer stopped (2026-07-23) for reasons the sponsor has not stated. Source

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (1)
Other / comorbidity
NCT00003873 · National Cancer Institute (NCI)
1999-04 – 2007-07 · Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
What this study did
Phase 2 (3)
Metastatic Colorectal Cancer
NCT00004195 · University of Alabama at Birmingham
1998-09 – 2001-05 · Colorectal Cancer
What this study did
Other / comorbidity
NCT01231802 · Adherex Technologies, Inc.
2011-04 – 2013-01 · Metastatic Breast Cancer
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT00005050 · NYU Langone Health
1999-08 – 2001-06 · Colorectal Cancer
What this study did
Phase 1 (2)
Other / comorbidity
NCT04861987 · Processa Pharmaceuticals
2021-06-18 – 2024-09-09 · Advanced Cancer, Refractory Cancer, Tumor Gastric
What this study did
NCT00827580 · West Virginia University
2009-01 – 2009-09 · Breast Cancer, Colon Cancer
What this study did

Competitive landscape

This drug's own stage for Metastatic Colorectal Cancer: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Eniluracil: this drugPhase 2—Dihydropyrimidine dehydrogenase (DPD)not yet gradedNo reviewed efficacy summary in this indication
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
BevacizumabApprovedMonoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor Inhibitornot yet gradedNo reviewed efficacy summary in this indication
Bevacizumab-Awwb (MVASI)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Capecitabine
ApprovedUS marketing discontinued
Small moleculeFluoropyrimidine (antimetabolite)not yet gradedNo reviewed efficacy summary in this indication
CetuximabApprovedMonoclonal antibodyEGFRPartial signal
NCT00154102: Progression-free survival (IRC), cetuximab + FOLFIRI vs FOLFIRI: median 8.9 vs 8.0 months, hazard ratio 0.853 (95% CI 0.728 to 1.000), p=0.0479 (n=599 each). Later KRAS analyses: wild-type HR 0.696 (95% CI 0.558 to 0.867), p=0.0012; mutant HR 1.171 (95% CI 0.887 to 1.544), p=0.2648 (CT.gov posted results).
EncorafenibApprovedSmall moleculeBRAF V600Enot yet gradedNo reviewed efficacy summary in this indication
Fruquintinib (Fruzaqla / Elunate)ApprovedSmall moleculeVEGFR1/2/3Reliable signal
NCT04322539: Median overall survival 7.4 months with fruquintinib (95% CI 6.7 to 8.2) vs 4.8 months with placebo (95% CI 4.0 to 5.8); stratified HR 0.662 (95% CI 0.549 to 0.800), p<.001
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistnot yet gradedNo reviewed efficacy summary in this indication
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
NivolumabApprovedMonoclonal antibodyPD-1Weak signalNo reviewed efficacy summary in this indication
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Weak signal
NCT02460198: Objective Response Rate (ORR) - Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) Assessed by Central Imaging Vendor (Up to approximately 48 months): Cohort A - Pembrolizumab 200 mg 32.8 Percentage of participants (95% CI 21.3 to 46) | Cohort B - Pembrolizumab 200 mg 34.9 Percentage of participants (95% CI 23.3 to 48)
RamucirumabApprovedMonoclonal antibodyVEGFR2Partial signal
NCT01183780: Overall Survival (OS) (Randomization to Date of Death from Any Cause Up to 39.36 Months): Ramucirumab + FOLFIRI 13.3 months (95% CI 12.4 to 14.5) | Placebo + FOLFIRI 11.7 months (95% CI 10.8 to 12.7)
RegorafenibApprovedSmall moleculeMulti-kinase inhibitor (VEGFR/PDGFR/KIT)Reliable signal
NCT01584830: Overall survival: hazard ratio 0·55 regorafenib vs placebo (median 8·8 months vs 6·3 months; one-sided p=0·00016)
SotorasibApprovedSmall moleculeKRAS G12Cnot yet gradedNo reviewed efficacy summary in this indication
TucatinibApprovedSmall moleculeHER2Partial signal
NCT03043313: Confirmed Objective Response Rate (cORR) Per RECIST v1.1 Per Blinded Independent Central Review (BICR) in Pooled Cohorts A+B (Up to 46.6 months): Tucatinib+Trastuzumab (Cohorts A+B) 39.3 Percentage of Participants (95% CI 28.8 to 50.5)
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Zirabev (bevacizumab-Bvzr)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Iparomlimab And TuvonralimabPhase 3Multispecific antibodyPD-1 x CTLA-4not yet gradedNo reviewed efficacy summary in this indication
IvonescimabPhase 3Multispecific antibodyPD-1 + VEGFAnot yet gradedNo reviewed efficacy summary in this indication
Precemtabart TocentecanPhase 3Antibody–drug conjugateCEACAM5not yet gradedNo reviewed efficacy summary in this indication
LeronlimabPhase 2Monoclonal antibodyCCR5 co-receptornot yet gradedNo reviewed efficacy summary in this indication
LYL273
Phase 1/2(overall)
Cell therapyGCC (guanylyl cyclase C, GUCY2C)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.